Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
Status:
Recruiting
Trial end date:
2025-06-30
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of hormonal therapy, chemotherapy, and
immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The
names of the study drugs involved in this study are:
- Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may
include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon).
- Docetaxel
- Nivolumab